1
00:00:00,000 --> 00:00:04,250
Some damaged cells enter senescence and remain in tissue.

2
00:00:04,250 --> 00:00:10,917
FOXO4-DRI was designed to test whether a protein interaction helps certain senescent cells stay alive.

3
00:00:10,917 --> 00:00:16,792
In the original study, the peptide disrupted an interaction involving FOXO4 and p53.

4
00:00:16,792 --> 00:00:21,875
Selected senescent cells then underwent programmed cell death in laboratory experiments.

5
00:00:21,875 --> 00:00:27,333
Researchers also reported tissue-function changes in mouse models of aging and chemotherapy-related

6
00:00:27,333 --> 00:00:32,417
injury. These experiments tested particular models, not anti-aging treatment in people.

7
00:00:32,417 --> 00:00:39,083
A later study reported lung-circulation changes and loss of lung blood-vessel lining cells in mice

8
00:00:39,083 --> 00:00:43,333
engineered to overexpress the serotonin transporter and given FOXO4-DRI.

9
00:00:43,333 --> 00:00:49,208
This raises a model-specific safety concern; it does not quantify risk in people.

10
00:00:49,208 --> 00:00:55,458
That distinction matters. A mechanism and animal results do not establish human rejuvenation, long-term

11
00:00:55,458 --> 00:00:58,958
safety or which people might benefit.

12
00:00:58,958 --> 00:01:02,458
Those remain separate research questions.